Endo, INC 8-K filings

Mallinckrodt plc has completed its acquisition of Endo, Inc., which subsequently converted into Endo LP, a Delaware limited partnership, and delisted its common stock from the OTCQX Best Market.

Endo, Inc. announced the successful outcomes of its 2025 Annual Meeting of Shareholders, confirming the re-election of all directors, advisory approval of executive compensation, and a commitment to annual advisory votes on executive pay.

Shareholders of Mallinckrodt plc and Endo, Inc. have overwhelmingly approved the proposed stock and cash transaction, clearing a major hurdle for the creation of a global, diversified pharmaceuticals leader.

Endo, Inc. reports a 6% decrease in total revenues for the first quarter of 2025 but reaffirms its full-year financial guidance.

Mallinckrodt and Endo have announced a proposed business combination, with Mallinckrodt filing a registration statement with the SEC.

Endo Inc. has approved cash retention bonuses for its executive officers to incentivize them to remain with the company and facilitate the completion of its merger with Mallinckrodt plc.

Endo, Inc. and Mallinckrodt plc have entered into a definitive transaction agreement for a business combination, pending shareholder and regulatory approvals.

Mallinckrodt and Endo have announced a definitive agreement to combine in a stock and cash transaction, aiming to create a global, scaled, diversified pharmaceuticals leader.

Endo Inc. has extended the term of its interim CEO, Scott Hirsch, to August 15, 2025, and increased his monthly base compensation to $750,000, effective January 1, 2025.

Endo's third-quarter results show a mixed performance with revenue declines in some segments offset by growth in others, while the company reaffirms its full-year financial expectations.

Endo Inc. has successfully refinanced its outstanding initial term loans, securing a 0.50% reduction in interest rate margins.

Endo Inc. estimates Q3 2024 revenue at $425 million and adjusted EBITDA at $150 million, reaffirming its full-year guidance.

Endo Inc. has approved performance and retention awards for senior officers and employees, along with new stock incentive plan award notices.

Endo Inc. provides an investor presentation detailing its financial restructuring, business segments, and growth strategies, including a focus on its XIAFLEX product line and pipeline.

Endo Inc. has announced the departure of CEO Blaise Coleman, effective August 29, 2024, and the appointment of Scott Hirsch as Interim CEO while a search for a permanent replacement is conducted.

Endo, Inc. announced its second-quarter 2024 financial results, exceeding internal expectations, leading to an increased full-year 2024 financial outlook and the provision of 2025 financial expectations.